公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2012 | Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Study | Johnson, Phillip; Qin, Shukui; Park, Joong-Won; Poon, Ronnie T.; Raoul, Jean-Luc; Philip, Philip A.; Hsu, Chih-Hung; Hu, Tsung-Hui; Heo, Jeong; Xu, Jianming; Lu, Ligong; Chao, Yee; Boucher, Eveline; Han, Kwang-Hyub; Paik, Seung Woon; Robles-Avina, Jorge; Kudo, Masatoshi; Liu, David; Ezzeddine, Rana; Walters, Ian; Cheng, Ann-Lii | Hepatology | | | |
2023 | Safety and dose escalation of the targeted oncolytic adenovirus OBP-301 for refractory advanced liver cancer: Phase I clinical trial | Heo, Jeong; JA-DER LIANG ; Kim, Chang Won; Woo, Hyun Young; I-LUN SHIH ; TUNG-HUNG SU ; ZHONG-ZHE LIN ; Yoo, So Young; Chang, Stanley; Urata, Yasuo; PEI-JER CHEN | Molecular therapy : the journal of the American Society of Gene Therapy | 4 | 1 | |
2014 | Safety and efficacy outcomes of all-oral daclatasvir-containing regimens in patients with or without cirrhosis in phase 2 and 3 studies | Jensen, Donald M.; Jacobson, Ira M.; Kumada, Hiromitsu; Toyota, Joji; Sulkowski, Mark S.; Manns, Michael P.; Kao, Jia-Horng; Heo, Jeong; Yin, Philip; Mendez, Patricia; Hughes, Eric A.; Noviello, Stephanie | Hepatology | | | |
2014 | Safety and efficacy outcomes of all-oral daclatasvir-containing regimens in patients with or without cirrhosis in phase 2 and 3 studies | Jensen, Donald M.; Jacobson, Ira M.; Kumada, Hiromitsu; Toyota, Joji; Sulkowski, Mark S.; Manns, Michael P.; Kao, Jia-Horng; Heo, Jeong; Yin, Philip; Mendez, Patricia; Hughes, Eric A.; Noviello, Stephanie | Hepatology | | | |